A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers

Exclusion Criteria

• •Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP
• •History of psychiatric or somatic disease/condition that may interfere with the objectives of the study, as judged by the investigator.